Has anyone done a bit of reading on the above mentioned adaptive platform trial?
I see they are finishing up the current trial and plan to launch a new, better one soon. The new trial will be in collaboration with the Global Coalition for Adaptive Research (GCAR).
For anyone not familiar with adaptive platform trials, they are usually phase 2/3 trials with rolling addition of new cohorts of novel therapies as they get accepted into the trial. Usually a single control group to benchmark against all the other cohorts.
Saves heaps time and money for companies developing novel therapies.
https://pancan.org/research/precision-promise/
PanCAN Precision Promise
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.8¢ |
Change
-0.001(1.01%) |
Mkt cap ! $35.10M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.7¢ | $39.76K | 404.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 35000 | 9.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.8¢ | 19833 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| ATX (ASX) Chart |